Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1136/gutjnl-2021-324116

Type

Journal article

Publication Date

01/12/2021

Volume

70

Pages

2398 - 2400

Total pages

2

Keywords

COVID-19, inflammatory bowel disease, infliximab, paediatric gastroenterology, Antibodies, Monoclonal, Humanized, COVID-19, Humans, Inflammatory Bowel Diseases, Infliximab, Pandemics, SARS-CoV-2, United Kingdom